Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. reports developments as a clinical-stage biotechnology company focused on investigational antibody therapies for neurodegenerative disease and cancer. Its lead program, pepinemab, is an anti-SEMA4D antibody being developed for Alzheimer’s disease and other neurological indications, with additional clinical work in cancer, including head and neck cancer and melanoma immunotherapy settings.
Company news commonly covers pepinemab clinical data presentations, financial results, development financing, and corporate updates tied to listing status and OTC quotation. Vaccinex also reports activity involving its ActivMAb® platform, which uses viral display of complex antigens to support antibody discovery collaborations and project agreements.
Vaccinex (Nasdaq: VCNX) announced a virtual presentation by CEO Dr. Maurice Zauderer at the 12th Annual Jefferies London Healthcare Conference on November 18-19, 2021. Investors are invited for one-on-one meetings during this period. The presentation will be accessible from 8:00 am GMT on November 18 until 5:00 pm GMT on November 19. Additionally, the presentation and a replay will be available on Vaccinex's website post-event. The company is focused on treating cancer and neurodegenerative diseases through SEMA4D inhibition, with its lead candidate, pepinemab, currently in clinical evaluation.
Vaccinex, Inc. (Nasdaq: VCNX) announced on November 1, 2021, that Dr. Maurice Zauderer will present at the Virtual Huntington Study Group Meeting on November 5. His presentation will discuss a positive post-hoc subgroup analysis from the SIGNAL Phase 2 trial of pepinemab, indicating cognitive benefits for patients with mildly advanced Huntington's Disease (HD). Dr. Elizabeth E. Evans will also present a related poster. Vaccinex is focused on advancing pepinemab, targeting both neurodegenerative diseases and cancer.
Vaccinex, a clinical-stage biotech firm, announced that COO Elizabeth Evans will present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021. The company is actively enrolling participants for its SIGNAL-AD trial on pepinemab for Alzheimer’s Disease and for the KEYNOTE B84 trial, combining pepinemab with Merck’s KEYTRUDA for head and neck cancer patients. The presentation will provide key insights into Vaccinex's innovative approach to targeting neurodegenerative diseases and cancer through SEMA4D inhibition.
Vaccinex announced promising findings from the SIGNAL Phase 2 Huntington’s Disease Trial presented by CEO Maurice Zauderer at the EHDN2021 meeting. The trial highlighted the cognitive benefits of the pepinemab antibody, especially in patients with moderately advanced HD. A pivotal Phase 3 trial is being planned, with ongoing discussions for potential development partners. The SIGNAL trial included 268 subjects and points towards treating cognitive impairments in HD, a currently incurable disease. The company aims to advance treatments for both HD and Alzheimer's disease.
Vaccinex, Inc. (Nasdaq: VCNX) reported Q2 2021 financial results, ending the period with $22.4 million in cash. The company has commenced two clinical studies: pepinemab as a monotherapy for Alzheimer’s disease and in combination with KEYTRUDA® for metastatic head and neck cancer. Positive interim data from the Huntington’s disease program highlights cognitive improvements and treatment efficacy. Upcoming milestones include topline data from Alzheimer’s trials expected in late 2022/early 2023 and early data from head and neck cancer studies anticipated in late 2022.
Vaccinex, Inc. (Nasdaq: VCNX) announced that Elizabeth Evans, PhD, will chair a symposium and present a poster at the XV European Meeting on Glial Cells in Health and Disease, held virtually from July 5 to 9, 2021. The symposium focuses on targeting glial cell activation for neurodegenerative disease treatment. Dr. Evans will discuss the clinical evaluation of pepinemab, a SEMA4D blocking antibody for Huntington's Disease and its Phase 1b/2a trial in Alzheimer’s Disease. The poster presentation will detail findings from these clinical trials.
Vaccinex (Nasdaq: VCNX) announced the activation of clinical sites for two significant studies. They aim to enroll at least 40 patients in a Phase 1/2 Alzheimer’s study evaluating pepinemab and 65 patients in a Phase 2 study assessing pepinemab in combination with Merck’s KEYTRUDA for advanced head and neck squamous cell carcinoma. Notable support comes from the Alzheimer’s Drug Discovery Foundation. The studies will measure cognition, brain imaging, and various efficacy endpoints, crucial for developing new therapies in neurodegenerative diseases and cancer.
Vaccinex, Inc. (Nasdaq: VCNX) announced that CEO Dr. Maurice Zauderer will present at the 2021 Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation is scheduled for June 1 at 4:30 PM ET, focusing on advancements in Vaccinex's neurology programs targeting Huntington’s and Alzheimer’s diseases, and their collaboration with Merck for head and neck cancer immunotherapy using pepinemab and KEYTRUDA®. A live video webcast will be available on the Vaccinex website post-presentation.
Vaccinex, Inc. (VCNX) has initiated a Phase 2 study of pepinemab combined with KEYTRUDA® for advanced head and neck cancer. The company announced positive results from the CLASSICAL-Lung trial published in Clinical Cancer Research, showing pepinemab's clinical activity in non-small cell lung cancer. Financially, Vaccinex raised $32 million through an open sale market agreement. For Q1 2021, revenue reached $850,000, with R&D expenses of $5.5 million. The company plans to start a Phase 1/2a trial for Alzheimer’s disease by Q2 2021.
Vaccinex, Inc. (Nasdaq: VCNX) announced the publication of results from its CLASSICAL-Lung clinical trial, evaluating pepinemab in combination with BAVENCIO® for treating non-small cell lung cancer (NSCLC). The Phase 1b/2 trial demonstrated clinical activity and safety, with a disease control rate (DCR) of 81% among immunotherapy naïve patients and 59% among those resistant to prior therapies. The results indicate that pepinemab may enhance the efficacy of checkpoint inhibitors, especially in challenging cases including PD-L1 negative tumors. The full data set is published in Clinical Cancer Research.